Can whole genome sequencing improve Tuberculosis care?
- Conditions
- TuberculosisC01.221.500
- Registration Number
- RBR-66hpcw7
- Lead Sponsor
- Instituto de Ciências Biomédicas da Universidade de São Paulo - ICB/USP
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Both sexes. Be a patient of at least one of the six medical centers participating in this study during the data collection period. Patients with treatment failure or relapse in whom antimicrobial resistance is suspected, but diagnostic resistance tests have not been performed or who have a negative result for rifampicin resistance on the Xpert® MTB/RIF Ultra. Patients with a positive test for rifampicin resistance by Xpert® MTB/RIF Ultra. Patients with a negative test for resistance to rifampicin by the Xpert® MTB/RIF Ultra, but positive for resistance to any of the first-line drugs by the Hain ribbon genotypic tests (GenoType MTBDR). Patients with relapse and previous diagnosis of resistant Tuberculosis
Extrapulmonary tuberculosis at the time of diagnosis or diagnosed during the study. Negative culture. Co-infection with nontuberculous mycobacteria. Patients who change treatment centers during the study. Patients who wish to abandon the study
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method